XNCRXencor, Inc.
$24.63+139% 1Y
$24.63
$10.3252 weeks$29.30
XNCR in its own filings
XNCR's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
234
Events found in the filings · across 890 filings · the record starts in 2013
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Oct 8, 2013
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Restatement admitted (non-reliance)past_3y
- 2025-02-13
- Change in certifying accountant3 occurrences
- 2025-03-13
- SEC comment-letter activity18 occurrences
- 2017-09-21
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Xencor Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 29, 2026On July 29, 2026, Xencor, Inc. (the “Company”) entered into a settlement agreement and release (the “Settlement Agreement”), with Alexion Pharma International Operations Limited, an Irish limited company (“Alexion”) with respect to a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz)Material agreement entered · Form 8-K
- May 6, 2026Xencor Reports First Quarter 2026 Financial Results.Earnings release · press release
- May 5, 2026® Designing Proteins Delivering Medicines Results from Phase 1 Study of XmAb942 & TL1A Pipeline Update May 5, 2026.Regulation FD disclosure · press release
- Apr 27, 2026On April 23, 2026, Xencor, Inc. (the “Company”) adopted the Xencor, Inc. Executive Severance Policy (the “Severance Policy”), pursuant to which certain executives of the Company, including the Company’s currently serving named executive officers with the exception of the Company’s Chief Executive Officer (our “NEOs”) …Director or officer change · Form 8-K
- Mar 9, 2026On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of June 1, 2024, with Genentech, Inc. (“GNE”) and F. Hoffmann-La Roche Ltd (“Roche” and, GNE and Roche, collectively, “Genentech”), pursuant to …Material agreement terminated · Form 8-K
- Mar 4, 2026Xencor Announces Change to Ultomiris® Royalty Revenue Forecast.Regulation FD disclosure · press release
- Feb 25, 2026Xencor Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Jan 8, 2026Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones.Earnings release · press release
- Nov 5, 2025Xencor Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Oct 24, 2025® Initial Results from Ongoing Dose-Escalation Study of XmAb819 & Oncology Pipeline Update October 24, 2025.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks